Danaher Corp (DHR) Stock Price, Quote & News

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 202 828 0850

Fax: 202 828 0860

Website: www.danaher.com

Address:

2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States

Iightning Nov. 19 at 5:26 AM

1ightning® Options Trade Alert (Actionable) | Buy $DHR Dec 5 $230 Call | Enter: $3.56 Exit: $5.26 | Profit: 47.79% ROI | https://1ightning.com

0 · Reply

trading_momentum_x Nov. 19 at 4:06 AM

$DHR on watch here, another healthcare name. Bullish engulfing today.

0 · Reply

LudicrousReturns Nov. 19 at 3:53 AM

18 NOV 2025 Ludicrous Returns Stock Model Update Sell Now: CSIQ, VECO (Stop Sell) price of Monday buys: IDAI (4.14), IRWD (2.46), QNRX (14.14), PALI (1.56), REGN (595.53), SHIP (7.96), SPRU (4.37) Updated Stop Sell: AMD (220.49) Buy Now: $ALXO, $DHR, $LAR Two buys with big growth potential that are very close to buy trigger: BIIB, VRA

0 · Reply

jdlman Nov. 18 at 3:47 PM

$DHR get invested

0 · Reply

stingrae Nov. 18 at 12:53 PM

$DHR Anyone listen to the Jeffries presentation this morning?

0 · Reply

stingrae Nov. 17 at 6:53 PM

$DHR Bullish weekly options in $222.5 and $227.5 strikes.

0 · Reply

Trader_Ty Nov. 17 at 2:14 PM

$DHR Haven't looked at this one in a bit. Pullback around 210 would set up a trade. Gots ATH look long term and this could be the start of it

0 · Reply

hoganbear Nov. 14 at 11:38 AM

$DHR now y’all have pissed off Danny Hurr..,when Danny hurr is mad, it means shit is fucked up

0 · Reply

JackDarwin Nov. 13 at 12:28 PM

$DHR Three White Soldiers Candlestick Pattern

0 · Reply

OfficialStocktwitsUser Nov. 13 at 8:51 AM

$DHR RSI: 43.48, MACD: 2.2683 Vol: 4.54, MA20: 215.12, MA50: 204.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

3 More Good Stocks to Invest In After Earnings

FTNT LPLA

Nov 18, 2025, 8:28 AM EST - 22 hours ago

Danaher Corporation (DHR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 13, 2025, 12:50 PM EST - 5 days ago

The Big 3: TMO, DHR, VLO

TMO VLO

Nov 11, 2025, 4:15 PM EST - 7 days ago

Danaher to Present at Jefferies Global Healthcare Conference

Nov 1, 2025, 11:00 PM EDT - 17 days ago

Top 15 High-Growth Dividend Stocks For November 2025

ACN APH AWK BMI CHH CMCSA CTAS

Oct 30, 2025, 4:10 PM EDT - 19 days ago

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Oct 27, 2025, 7:53 PM EDT - 22 days ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Oct 26, 2025, 5:50 PM EDT - 23 days ago

DHR Announcement: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Oct 24, 2025, 11:52 AM EDT - 25 days ago

Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 1:01 PM EDT - 27 days ago

These Analysts Increase Their Forecasts On Danaher Following Upbeat Q3 Earnings

Oct 22, 2025, 10:49 AM EDT - 27 days ago

Danaher: Regaining Growth Momentum

Oct 22, 2025, 8:10 AM EDT - 27 days ago

Danaher Still A Hold: Good Q3 Results Alone Don't Make A Great Investment

Oct 21, 2025, 11:14 AM EDT - 4 weeks ago

Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript

Oct 21, 2025, 10:55 AM EDT - 4 weeks ago

Is Danaher's Q3 beat enough to reignite long-term growth for DHR investors?

Oct 21, 2025, 7:01 AM EDT - 4 weeks ago

Danaher beats quarterly estimates on strength in diagnostic tools and tech

Oct 21, 2025, 6:23 AM EDT - 4 weeks ago

Danaher Sales and Profit Rise on Bioprocessing Momentum

Oct 21, 2025, 6:00 AM EDT - 4 weeks ago

Danaher Reports Third Quarter 2025 Results

Oct 16, 2025, 10:18 PM EDT - 4 weeks ago

Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Oct 15, 2025, 10:25 AM EDT - 4 weeks ago

Danaher Stock: Monopoly Margins, Discounted Price

Oct 6, 2025, 2:45 PM EDT - 6 weeks ago

4 Stocks That Aren't Too Hot to Buy Right Now

EVRG KNTK PWR XLU

Oct 1, 2025, 6:33 AM EDT - 7 weeks ago

Danaher: Balanced Portfolio With Upside Potential In 2026

Sep 23, 2025, 4:15 PM EDT - 2 months ago

Danaher Schedules Third Quarter 2025 Earnings Conference Call

Sep 11, 2025, 2:26 PM EDT - 2 months ago

Analysts' Top S&P 500 Stocks to Buy Now

HWM SPGI

Sep 10, 2025, 8:31 AM EDT - 2 months ago

Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

Sep 9, 2025, 4:15 PM EDT - 2 months ago

Danaher Announces Quarterly Dividend

Sep 5, 2025, 8:39 PM EDT - 2 months ago

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX GRAL ILMN IONS MRNA RGEN

Aug 4, 2025, 7:13 AM EDT - 3 months ago

Danaher Stock Closes Near Day's High After Key Trading Signal

Jul 31, 2025, 4:15 PM EDT - 3 months ago

Danaher Appoints Jonathan Leiken as General Counsel

Jul 24, 2025, 8:08 PM EDT - 4 months ago

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

Jul 24, 2025, 3:30 PM EDT - 4 months ago

Danaher Q2 2025 Update

Jul 23, 2025, 9:50 AM EDT - 4 months ago

Danaher Stock: Attractively Valued And Poised For Growth Acceleration

Jul 22, 2025, 1:18 PM EDT - 4 months ago

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 10:33 AM EDT - 4 months ago

Cramer's Stop Trading: Danaher

Jul 22, 2025, 7:51 AM EDT - 4 months ago

Danaher lifts annual profit view on strength in diagnostics, names new CFO

Jul 22, 2025, 6:02 AM EDT - 4 months ago

Danaher Announces Transition Plan for Chief Financial Officer

Jul 22, 2025, 6:00 AM EDT - 4 months ago

Danaher Reports Second Quarter 2025 Results

Jul 17, 2025, 9:14 AM EDT - 4 months ago

45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs

AEP AGNC ALL FAF FLMI GDEN JAAA

Jun 30, 2025, 4:23 AM EDT - 5 months ago

Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside

Jun 27, 2025, 7:35 AM EDT - 5 months ago

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Jun 27, 2025, 7:30 AM EDT - 5 months ago

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

Jun 19, 2025, 12:33 PM EDT - 5 months ago

Danaher: High Capex And Low Debt Despite Trump Legislation

Jun 17, 2025, 4:30 PM EDT - 5 months ago

Danaher Schedules Second Quarter 2025 Earnings Conference Call

Jun 4, 2025, 9:00 AM EDT - 5 months ago

Prosperity Partners Completes Acquisition of Danaher Attig & Plante

Jun 2, 2025, 7:00 AM EDT - 6 months ago

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

Jun 2, 2025, 7:00 AM EDT - 6 months ago

Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

Jun 2, 2025, 7:00 AM EDT - 6 months ago

SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

May 29, 2025, 4:30 PM EDT - 6 months ago

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

AZN

Iightning Nov. 19 at 5:26 AM

1ightning® Options Trade Alert (Actionable) | Buy $DHR Dec 5 $230 Call | Enter: $3.56 Exit: $5.26 | Profit: 47.79% ROI | https://1ightning.com

0 · Reply

trading_momentum_x Nov. 19 at 4:06 AM

$DHR on watch here, another healthcare name. Bullish engulfing today.

0 · Reply

LudicrousReturns Nov. 19 at 3:53 AM

0 · Reply

jdlman Nov. 18 at 3:47 PM

$DHR get invested

0 · Reply

stingrae Nov. 18 at 12:53 PM

$DHR Anyone listen to the Jeffries presentation this morning?

0 · Reply

stingrae Nov. 17 at 6:53 PM

$DHR Bullish weekly options in $222.5 and $227.5 strikes.

0 · Reply

Trader_Ty Nov. 17 at 2:14 PM

$DHR Haven't looked at this one in a bit. Pullback around 210 would set up a trade. Gots ATH look long term and this could be the start of it

0 · Reply

hoganbear Nov. 14 at 11:38 AM

$DHR now y’all have pissed off Danny Hurr..,when Danny hurr is mad, it means shit is fucked up

0 · Reply

JackDarwin Nov. 13 at 12:28 PM

$DHR Three White Soldiers Candlestick Pattern

0 · Reply

OfficialStocktwitsUser Nov. 13 at 8:51 AM

0 · Reply

CharlesHall273 Nov. 12 at 3:17 PM

$DHR expands diagnostics and bioprocessing solutions with strong M&A integration and recurring revenue model. AERT recently turned profitable in Q2 FY2026, reporting $17.36 M revenue and $0.64 M net income, highlighting momentum in its AI-led global delivery model. https://www.youtube.com/watch?v=d2BieklTnl4

0 · Reply

TechTraderGrok Nov. 11 at 10:29 PM

Bought $DHR at $215.9. From Grok: "Enter long on DHR's confirmed uptrend with price above rising EMA/SMA, rebound above prior support at 211 after recent exit, positive momentum signals like improving MACD/RSI, and favorable risk/reward targeting resistance near 225 over weeks, justified quick re-entry due to sustained recovery and no lingering fade." https://www.techtrader.ai/grokwall/?post=15504&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

DavidMacph1 Nov. 11 at 5:56 PM

$DHR - optimal entry would have been end of September for a PT +30% upside. Now that it's run a bit and broken out I wouldn't chase it, likely has 15-20% reasonable upside left. IMHO there's better names you can buy that are offer optimal risk to reward $SN $BSX $DXCM

0 · Reply

TechTraderGrok Nov. 6 at 9:11 PM

Sold $DHR at $211.26 (-4.4%). From Grok: "Exit long DHR as price breached key support below 211 with fading post-earnings momentum and no major catalysts ahead, locking in position amid unclear upside potential." https://www.techtrader.ai/grokwall/?post=15468&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

RunnerSignals Nov. 5 at 4:45 AM

Dip but not done yet $NEE $RTX $DHR $IQV $BTDR all cooling off but still flexing that uptrend muscle. are these just breathers before the next bounce?

1 · Reply

hoganbear Nov. 4 at 4:16 PM

$DHR if DHR is green, markets will reverse lol $SPY

1 · Reply

NVDAMillionaire Nov. 3 at 10:19 PM

$DHR Excellent article that nails exactly where DHR stands right now. So if you want to update your DHR knowledge or get acquainted with DHR, this is a must read. https://beyondspx.com/quote/DHR/analysis/danaher-s-resilient-growth-engine-innovation-and-operational-excellence-drive-future-value-nyse-dhr

0 · Reply

SqueezeChronometer Nov. 2 at 11:23 AM

Next major retail squeeze candidate right here $SPSC $CHGG $DHR $XYL <

1 · Reply

rgmac12 Oct. 29 at 11:41 PM

$DHR dog with fleas

0 · Reply

_Solar_Drift_ Oct. 29 at 6:14 PM

$DHR life sciences exposure still appealing for defensive positioning.

0 · Reply

smartkarma Oct. 24 at 6:04 PM

$DHR | Danaher Corporation Is Powering Ahead With Explosive Bioprocessing Growth; But These Are The 4 Biggest Challenges Ahead! "Danaher Corporation's third-quarter 2025 earnings showcased a balanced performance underpinned by solid demand in certain sectors, yet offset by..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/danaher-corporation-is-powering-ahead-with-explosive-bioprocessing-growth-but-these-are-the-4-biggest-challenges-ahead

0 · Reply

SuperGreenToday Oct. 23 at 10:05 PM

$DHR Share Price: $222.64 Contract Selected: Nov 14, 2025 $225 Calls Buy Zone: $3.82 – $4.73 Target Zone: $7.24 – $8.85 Potential Upside: 79% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	155.71B
Revenue (ttm)	23.88B
Net Income (ttm)	3.90B
EPS (ttm)	N/A
PE Ratio	28.69
Forward PE	28.67
Profit Margin	16.33%
Debt to Equity Ratio	0.33

Volume	5,311,300
Avg Vol	4,417,162
Day's Range	N/A - N/A
Shares Out	706.35M
Stochastic %K	93%
Beta	0.81
Analysts	Strong Sell
Price Target	$251.68